Comprehensive molecular profiling of sarcomas in adolescent and young adult patients: Results of the EORTC SPECTA-AYA international proof-of-concept study
Name:
36470093.pdf
Size:
1.515Mb
Format:
PDF
Description:
Identified with Open Access button
Authors
Morfouace, M.Horak, P.
Kreutzfeldt, S.
Stevovic, A.
de Rojas, T.
Denisova, E.
Hutter, B.
Bautista, F.
Oliveira, J.
Defachelles, A. S.
White, J.
Kasper, B.
Preusser, M.
Golfinopoulos, V.
Pfister, S.
Van der Graaf, W.
Wardelmann, E.
Shenjere, Patrick
Fröhling, S.
McCabe, Martin G
Affiliation
European Organisation for the Research and Treatment of Cancer (EORTC), Brussels, BelgiumIssue Date
2022
Metadata
Show full item recordAbstract
Background: Adolescent and young adult (AYA) patients with cancer are poorly recruited to molecularly targeted trials and have not witnessed the advances in cancer treatment and survival seen in other age groups. We report here a pan-European proof-of-concept study to identify actionable alterations in some of the worst prognosis AYA cancers: bone and soft tissue sarcomas. Design: Patients aged 12-29 years with newly diagnosed or recurrent, intermediate or high-grade bone and soft tissue sarcomas were recruited from six European countries. Pathological diagnoses were centrally reviewed. Formalin-fixed tissues were analysed by whole exome sequencing, methylation profiling and RNA sequencing and were discussed in a multidisciplinary, international molecular tumour board. Results: Of 71 patients recruited, 48 (median 20 years, range 12-28) met eligibility criteria. Central pathological review confirmed, modified and re-classified the diagnosis in 41, 3, and 4 cases, respectively. Median turnaround time to discussion at molecular tumour board was 8.4 weeks. whole exome sequencing (n = 48), methylation profiling (n = 44, 85%) and RNA sequencing (n = 24, 50%) led to therapeutic recommendations for 81% patients, including 4 with germ line alterations. The most common were for agents targeted towards tyrosine kinases (n = 20 recommendations), DNA repair (n = 18) and the PI3K/mTOR/AKT pathway (n = 15). Recommendations were generally based on weak evidence such as activity in a different tumour type (n = 68, 61%), reflecting the dearth of relevant molecular clinical trial data in the same tumour type. Conclusions: We demonstrate here that comprehensive molecular profiling of AYA patients' samples is feasible and deliverable in a European programme.Citation
Morfouace M, Horak P, Kreutzfeldt S, Stevovic A, de Rojas T, Denisova E, et al. Comprehensive molecular profiling of sarcomas in adolescent and young adult patients: Results of the EORTC SPECTA-AYA international proof-of-concept study. European journal of cancer (Oxford, England : 1990). 2022 Nov 5;178:216-26. PubMed PMID: 36470093. Epub 2022/12/06. eng.Journal
European Journal of CancerDOI
10.1016/j.ejca.2022.10.020PubMed ID
36470093Additional Links
https://dx.doi.org/10.1016/j.ejca.2022.10.020Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.ejca.2022.10.020
Scopus Count
Collections
Related articles
- EORTC SPECTA-AYA: A unique molecular profiling platform for adolescents and young adults with cancer in Europe.
- Authors: de Rojas T, Kasper B, Van der Graaf W, Pfister SM, Bielle F, Ribalta T, Shenjere P, Preusser M, Fröhling S, Golfinopoulos V, Morfouace M, McCabe MG
- Issue date: 2020 Aug 15
- Next-generation personalised medicine for high-risk paediatric cancer patients - The INFORM pilot study.
- Authors: Worst BC, van Tilburg CM, Balasubramanian GP, Fiesel P, Witt R, Freitag A, Boudalil M, Previti C, Wolf S, Schmidt S, Chotewutmontri S, Bewerunge-Hudler M, Schick M, Schlesner M, Hutter B, Taylor L, Borst T, Sutter C, Bartram CR, Milde T, Pfaff E, Kulozik AE, von Stackelberg A, Meisel R, Borkhardt A, Reinhardt D, Klusmann JH, Fleischhack G, Tippelt S, Dirksen U, Jürgens H, Kramm CM, von Bueren AO, Westermann F, Fischer M, Burkhardt B, Wößmann W, Nathrath M, Bielack SS, Frühwald MC, Fulda S, Klingebiel T, Koscielniak E, Schwab M, Tremmel R, Driever PH, Schulte JH, Brors B, von Deimling A, Lichter P, Eggert A, Capper D, Pfister SM, Jones DT, Witt O
- Issue date: 2016 Sep
- Prognostic factors in adolescents and young adults (AYA) with high risk soft tissue sarcoma (STS) treated by adjuvant chemotherapy: a study based on pooled European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62771 and 62931.
- Authors: Kasper B, Ouali M, van Glabbeke M, Blay JY, Bramwell VH, Woll PJ, Hohenberger P, Schöffski P
- Issue date: 2013 Jan
- Clinical application of genomic profiling to find druggable targets for adolescent and young adult (AYA) cancer patients with metastasis.
- Authors: Cha S, Lee J, Shin JY, Kim JY, Sim SH, Keam B, Kim TM, Kim DW, Heo DS, Lee SH, Kim JI
- Issue date: 2016 Feb 29
- Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas.
- Authors: Groisberg R, Hong DS, Holla V, Janku F, Piha-Paul S, Ravi V, Benjamin R, Kumar Patel S, Somaiah N, Conley A, Ali SM, Schrock AB, Ross JS, Stephens PJ, Miller VA, Sen S, Herzog C, Meric-Bernstam F, Subbiah V
- Issue date: 2017 Jun 13